ZymoGenetics

From Wikipedia, the free encyclopedia
Jump to: navigation, search
ZymoGenetics
Public
Industry Biotechnology/Pharmaceuticals
Founded 1981 (1981) in Seattle, Washington
Founders Earl W. Davie, Michael Smith and Benjamin D. Hall
Key people
Stephanie Feldt
Products Pharmaceuticals
Owner Bristol-Myers Squibb
Website http://www.bms.com/ourcompany/our_operations/Pages/zymogenetics.aspx


ZymoGenetics, Inc is one of the oldest biotechnology/pharmaceutical companies in the USA,[1] based in Seattle, Washington. The company is involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters is 1201 Eastlake Avenue East.[2]

The company was founded in 1981[3] by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.[2] Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988.[4] It was spun off as a public company in 2000.[1] Bristol-Myers Squibb acquired the company in 2010 for $885 million.[5]

ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.[6]

Corporate governance[edit]

In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.[7]

References[edit]

  1. ^ a b Pollack, Andrew (23 October 2000). "ZymoGenetics Will Become Independent of Novo Nordisk". New York Times. Retrieved 21 May 2015. ZymoGenetics Inc. said it had arranged for $150 million in private financing that would allow it to become independent of its parent company, Novo Nordisk A.S. of Denmark. 
  2. ^ a b "ZymoGenetics, a Bristol-Myers Squibb Company". Bristol-Myers Squibb. Retrieved 21 May 2015. 
  3. ^ Timmerman, Luke (25 January 2011). "Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers". Xconomy. Retrieved 21 May 2015. ZymoGenetics, the venerable biotech founded in 1981. 
  4. ^ "Novo Nordisk completes divestment of ZymoGenetics, Inc.". Bionity.com. 13 October 2010. Retrieved 21 May 2015. Novo Nordisk has been a shareholder of ZymoGenetics since 1988 and at the time of the transaction, Novo Nordisk owned 22,143,320 shares, equalling close to 26% of the share capital. 
  5. ^ Carroll, John (8 September 2010). "BMS forges $885M deal to buy ZymoGenetics". FierceBiotech. Retrieved 21 May 2015. Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million. 
  6. ^ Timmerman, Luke (13 September 2010). "What Will Happen to ZymoGenetics’ Landmark Headquarters when Bristol Calls the Shots?". Xconomy. Retrieved 21 May 2015. 
  7. ^ Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Biopharma. Med Ad News. p. 27. 

External links[edit]